CN107106660B - 长效glp-1/胰高血糖素受体双激动剂对于治疗非酒精性脂肪肝疾病的应用 - Google Patents

长效glp-1/胰高血糖素受体双激动剂对于治疗非酒精性脂肪肝疾病的应用 Download PDF

Info

Publication number
CN107106660B
CN107106660B CN201580061525.9A CN201580061525A CN107106660B CN 107106660 B CN107106660 B CN 107106660B CN 201580061525 A CN201580061525 A CN 201580061525A CN 107106660 B CN107106660 B CN 107106660B
Authority
CN
China
Prior art keywords
glp
pharmaceutical composition
glucagon
glucagon receptor
long
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580061525.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN107106660A (zh
Inventor
黄祥渊
金真荣
金承洙
崔仁荣
郑圣烨
权世昌
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanmi Pharmaceutical Co Ltd
Original Assignee
Hanmi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55533503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN107106660(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharmaceutical Co Ltd filed Critical Hanmi Pharmaceutical Co Ltd
Publication of CN107106660A publication Critical patent/CN107106660A/zh
Application granted granted Critical
Publication of CN107106660B publication Critical patent/CN107106660B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201580061525.9A 2014-09-16 2015-09-16 长效glp-1/胰高血糖素受体双激动剂对于治疗非酒精性脂肪肝疾病的应用 Active CN107106660B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2014-0122862 2014-09-16
KR20140122862 2014-09-16
PCT/KR2015/009753 WO2016043533A1 (en) 2014-09-16 2015-09-16 Use of a long acting glp-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease

Publications (2)

Publication Number Publication Date
CN107106660A CN107106660A (zh) 2017-08-29
CN107106660B true CN107106660B (zh) 2021-10-22

Family

ID=55533503

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580061525.9A Active CN107106660B (zh) 2014-09-16 2015-09-16 长效glp-1/胰高血糖素受体双激动剂对于治疗非酒精性脂肪肝疾病的应用

Country Status (26)

Country Link
US (2) US10233230B2 (enExample)
EP (1) EP3197483A4 (enExample)
JP (2) JP6832273B2 (enExample)
KR (3) KR102541971B1 (enExample)
CN (1) CN107106660B (enExample)
AR (1) AR101896A1 (enExample)
AU (3) AU2015318881A1 (enExample)
CA (1) CA2960657A1 (enExample)
CL (1) CL2017000638A1 (enExample)
CO (1) CO2017002689A2 (enExample)
CR (1) CR20170129A (enExample)
EA (1) EA201790568A1 (enExample)
EC (1) ECSP17022931A (enExample)
GT (1) GT201700056A (enExample)
IL (2) IL251060B (enExample)
MA (1) MA40466A (enExample)
MX (2) MX2017003438A (enExample)
MY (2) MY178378A (enExample)
NI (1) NI201700032A (enExample)
NZ (1) NZ730799A (enExample)
PE (1) PE20170778A1 (enExample)
PH (1) PH12017500486A1 (enExample)
SG (1) SG11201701841WA (enExample)
TW (2) TWI772252B (enExample)
WO (1) WO2016043533A1 (enExample)
ZA (2) ZA201701847B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2721062T (pt) 2011-06-17 2019-02-12 Hanmi Science Co Ltd Conjugado que compreende oxintomodulina e um fragmento de imunoglobulina e utilização do mesmo
KR102311517B1 (ko) 2012-11-06 2021-10-14 한미약품 주식회사 옥신토모듈린과 면역글로불린 단편을 포함하는 단백질 결합체의 액상 제제
TWI772252B (zh) * 2014-09-16 2022-08-01 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
US11135271B2 (en) 2014-12-30 2021-10-05 Hanmi Pharm. Co., Ltd. Glucagon derivatives with improved stability
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
US10696725B2 (en) 2015-06-30 2020-06-30 Hanmi Pharm. Co., Ltd. Glucagon derivative and a composition comprising a long acting conjugate of the same
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
CN116063453A (zh) 2015-12-31 2023-05-05 韩美药品株式会社 胰高血糖素/glp-1/gip受体三重激动剂
CN106046145B (zh) * 2016-04-22 2022-11-04 深圳市图微安创科技开发有限公司 Glp-1r/gcgr双靶点激动剂多肽治疗脂肪肝病、高脂血症和动脉硬化
TN2018000452A1 (en) * 2016-06-29 2020-06-15 Hanmi Pharm Ind Co Ltd Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
WO2018143729A1 (ko) 2017-02-03 2018-08-09 한미약품 주식회사 지속성이 증가된 생리활성 물질의 결합체 및 이의 용도
CN111372945B (zh) * 2017-11-06 2024-02-02 中山大学 基于胃泌酸调节素类似物glp-1r/gcgr双靶点激动剂多肽治疗特发性肺间质纤维化
WO2019085772A1 (zh) * 2017-11-06 2019-05-09 深圳市图微安创科技开发有限公司 基于胃泌酸调节素类似物glp-1r/gcgr双靶点激动剂多肽治疗胆汁性肝硬化
EP3735295B1 (en) * 2018-01-03 2024-08-21 Mederis Diabetes, LLC Improved peptide pharmaceuticals for treatment of nash and other disorders
WO2019171352A2 (en) * 2018-03-08 2019-09-12 Janssen Pharmaceutica Nv Methods of treating severe non-diabetic obesity
CN112312922B (zh) * 2018-06-21 2025-04-11 诺和诺德股份有限公司 用于治疗肥胖症的新型化合物
WO2020128967A2 (en) * 2018-12-19 2020-06-25 Janssen Pharmaceutica Nv Methods of treating severe non-diabetic obesity
CN114853908B (zh) * 2019-05-16 2024-06-07 浙江道尔生物科技有限公司 一种治疗代谢疾病的融合蛋白
KR102227400B1 (ko) * 2019-06-28 2021-03-15 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체의 간 질환에 대한 치료적 용도
WO2021010531A1 (ko) * 2019-07-18 2021-01-21 한미약품 주식회사 단백질 결합체의 신규 제조 방법
KR20210103265A (ko) * 2020-02-13 2021-08-23 주식회사 제넥신 신규 비알코올성 지방간염 치료용 약학 조성물
KR102349717B1 (ko) * 2020-03-12 2022-01-11 주식회사 에스엘메타젠 신규 대사증후군 및 그와 관련된 질환 치료용 약학 조성물
US11135220B1 (en) 2020-04-08 2021-10-05 St Ip Holding Ag Methods of treating viral infections with formulated compositions comprising 4-methyl-5-(pyrazin-2-yl)-3H-1,2-dithiole-3-thione
CA3175852A1 (en) 2020-04-29 2021-11-04 Onegene Biotechnology Inc. Novel protein conjugate, and use thereof for preventing or treating nonalcoholic steatohepatitis, obesity and diabetes
CN113278060B (zh) * 2020-05-29 2022-03-25 东莞云璟生物技术有限公司 Glp-1/胰高血糖素双重激动剂融合蛋白
WO2022015039A1 (ko) * 2020-07-14 2022-01-20 (주)지아이이노베이션 글루카곤-유사 펩타이드-1 및 글루카곤-유사 펩타이드-2를 포함하는 융합 단백질 및 이의 용도
JP2023538236A (ja) * 2020-08-14 2023-09-07 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン、ｇｌｐ－１及びｇｉｐ受容体の全てに対して活性を有する三重活性体を含む血圧降下用薬学組成物
CN112472794A (zh) * 2020-11-17 2021-03-12 深圳市图微安创科技开发有限公司 双靶点激动剂多肽治疗anit介导的pbc及其相关的肝纤维化
KR102732028B1 (ko) * 2020-12-22 2024-11-19 (주)메디엔진 알코올성 및 비알코올성 지방간의 예방 또는 치료용 약학 조성물
CN112625093B (zh) * 2020-12-29 2022-12-23 清远市图微安创科技开发有限公司 用于预防和/或治疗非酒精性脂肪肝炎的多肽化合物
IL304214B2 (en) 2021-01-20 2025-01-01 Viking Therapeutics Inc Compositions and methods for treating metabolic and liver disorders
WO2022178366A1 (en) * 2021-02-21 2022-08-25 Spitfire Pharma Llc Glp-1r, gip-r and/or gcgr agonists, formulations, and methods of use
KR102873595B1 (ko) * 2021-09-15 2025-10-22 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 장애의 치료를 위한 조성물 및 방법
CN116589536B (zh) * 2023-05-18 2024-01-23 江苏师范大学 一类长效glp-1/gip受体双重激动剂及其应用

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102056606A (zh) * 2008-06-03 2011-05-11 贝林格尔.英格海姆国际有限公司 用于治疗非酒精性脂肪肝疾病的dpp-iv抑制剂
CN102123723A (zh) * 2008-06-17 2011-07-13 印第安纳大学研究及科技有限公司 胰高血糖素/glp-1受体共激动剂
CN102459325A (zh) * 2009-06-16 2012-05-16 印第安纳大学科技研究有限公司 胃抑胜肽受体活化的胰高血糖素化合物
CN102781458A (zh) * 2009-11-23 2012-11-14 安米林药品公司 多肽缀合物
CN103338760A (zh) * 2010-11-15 2013-10-02 贝林格尔.英格海姆国际有限公司 保护血管及保护心脏的抗糖尿病性治疗
TW201340981A (zh) * 2012-03-09 2013-10-16 Hanmi Science Co Ltd 用於預防或治療非酒精性脂肪肝疾病之醫藥組合物
CN103402536A (zh) * 2010-12-22 2013-11-20 马克迪亚生物科技公司 用gip和glp-1受体活性的基于胰高血糖素的肽来治疗代谢异常和肥胖的方法
WO2014017843A1 (en) * 2012-07-25 2014-01-30 Hanmi Pharm. Co., Ltd. Composition for treating hyperlipidemia comprising oxyntomodulin derivative
CN103596595A (zh) * 2011-06-02 2014-02-19 韩美科学株式会社 用于治疗糖尿病的包括长效胰岛素缀合物和长效促胰岛素肽缀合物的组合物
CN103906528A (zh) * 2011-06-24 2014-07-02 安米林药品有限责任公司 用glp-1受体激动剂的缓释制剂治疗糖尿病的方法

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
JP3895109B2 (ja) 1998-03-06 2007-03-22 中外製薬株式会社 蛋白非添加製剤
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
US7217845B2 (en) 2002-11-25 2007-05-15 Sun Bio, Inc. Bifunctional polyethylene glycol derivatives
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2005035761A1 (en) 2003-10-16 2005-04-21 Compugen Ltd. Splice variants of preproglucagon, glucagon-like peptide-1 and oxyntomodulin
KR101135244B1 (ko) 2007-11-29 2012-04-24 한미사이언스 주식회사 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
JP4762904B2 (ja) 2003-11-13 2011-08-31 ハンミ ホールディングス カンパニー リミテッド 免疫グロブリン不変領域の量産方法
US8263084B2 (en) 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
US20090238838A1 (en) 2003-11-13 2009-09-24 Hanmi Pharm. Ind. Co. Ltd. Insulinotropic peptide conjugate using an immunoglobulin fc
EP1841796A2 (en) 2004-12-02 2007-10-10 Domantis Limited Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
AU2006213607A1 (en) 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Llc GIP analog and hybrid polypeptides with selectable properties
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
PL1891105T3 (pl) 2005-06-13 2012-09-28 Imperial Innovations Ltd Analogi oksyntomoduliny i ich wpływ na zachowania żywieniowe
GB0511986D0 (en) 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
EP1922336B1 (en) 2005-08-11 2012-11-21 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
US20090297496A1 (en) * 2005-09-08 2009-12-03 Childrens Hospital Medical Center Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
WO2007100535A2 (en) 2006-02-22 2007-09-07 Merck & Co., Inc. Oxyntomodulin derivatives
CA2654055A1 (en) 2006-06-07 2007-12-21 Human Genome Sciences, Inc. Albumin fusion proteins
GB0624868D0 (en) 2006-12-13 2007-01-24 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
US20090098130A1 (en) 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
JP6017754B2 (ja) 2007-02-15 2016-11-02 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ グルカゴン／ｇｌｐ−１受容体コアゴニスト
BRPI0813699B1 (pt) 2007-07-10 2021-06-22 Eli Lilly And Company Formulação de proteína de fusão glp-1-fc
WO2009015763A1 (en) 2007-07-27 2009-02-05 Bayer Cropscience Ag Ternary active compound combinations
WO2009040068A2 (en) 2007-09-11 2009-04-02 Mondobiotech Laboratories Ag Use of a peptide as a therapeutic agent
CA2702289A1 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
JP2011511778A (ja) 2008-01-30 2011-04-14 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション エステルに基づいたペプチドプロドラッグ
EP2307037A4 (en) 2008-06-17 2011-08-03 Univ Indiana Res & Tech Corp GLUCAGON ANALOGUE WITH IMPROVED SOLUBILITY AND STABILITY IN PHYSIOLOGICAL PH BUFFERS
WO2010013012A2 (en) 2008-08-01 2010-02-04 Lund University Bioscience Ab Novel polypeptides and uses thereof
EP2898900B1 (en) 2008-09-19 2017-11-15 Nektar Therapeutics Polymer conjugates of ziconotide
US20110171312A1 (en) 2008-09-19 2011-07-14 Nektar Therapeutics Modified therapeutic peptides, methods of their preparation and use
PL2370461T3 (pl) 2008-12-15 2014-03-31 Zealand Pharma As Analogi glukagonu
AR074811A1 (es) 2008-12-19 2011-02-16 Univ Indiana Res & Tech Corp Profarmaco de peptido de la superfamilia de glucagon basados en amida
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
DK2408800T3 (en) 2009-03-20 2016-08-29 Hanmi Science Co Ltd A process for the preparation of a site-specific conjugate of a physiologically active polypeptide
CA2755133A1 (en) 2009-03-20 2010-09-23 Amgen Inc. Selective and potent peptide inhibitors of kv1.3
US9156901B2 (en) 2009-07-13 2015-10-13 Ditte Riber Acylated glucagon analogues
US20120294855A1 (en) 2009-11-03 2012-11-22 Eli Lilly & Company Glp-1 receptor agonist compounds for obstructive sleep apnea
US20120269830A1 (en) 2009-12-07 2012-10-25 Lawrence Horowitz Conjugates with improved pharmacokinetic properties
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
AR079345A1 (es) 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina
AR079344A1 (es) 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad
WO2011117415A1 (en) 2010-03-26 2011-09-29 Novo Nordisk A/S Novel glucagon analogues
KR20130111923A (ko) 2010-05-13 2013-10-11 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 G-단백결합 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드
CA2796894A1 (en) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
KR101337797B1 (ko) 2010-07-14 2013-12-06 한미사이언스 주식회사 지속형 인간 성장 호르몬 결합체 액상 제제
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
CN101974077A (zh) 2010-09-15 2011-02-16 南京瑞年天平医药科技有限公司 一种新颖的多肽化合物
KR101767570B1 (ko) 2010-10-26 2017-08-14 한미사이언스 주식회사 항 비만 펩타이드의 지속형 결합체
KR101303388B1 (ko) 2010-10-26 2013-09-03 한미사이언스 주식회사 지속형 인터페론 알파 결합체의 액상 제제
CN102010473A (zh) 2010-11-10 2011-04-13 曹鹏 重组胃泌酸调节素融合蛋白及其制备和应用
JP6118500B2 (ja) 2011-02-28 2017-04-19 ローム アンド ハース エレクトロニック マテリアルズ エルエルシーＲｏｈｍ ａｎｄ Ｈａａｓ Ｅｌｅｃｔｒｏｎｉｃ Ｍａｔｅｒｉａｌｓ ＬＬＣ フォトレジスト組成物、およびフォトリソグラフィパターンを形成する方法
KR101161526B1 (ko) 2011-05-16 2012-07-02 숭실대학교산학협력단 연료전지용 촉매전극을 위한 코어/쉘 구조의 나노 지지체 및 그 제조방법
AR086866A1 (es) 2011-06-10 2014-01-29 Hanmi Science Co Ltd Derivados de oxintomodulina y composicion farmaceutica que los comprende para el tratamiento de la obesidad
PT2721062T (pt) 2011-06-17 2019-02-12 Hanmi Science Co Ltd Conjugado que compreende oxintomodulina e um fragmento de imunoglobulina e utilização do mesmo
EP2723766A4 (en) 2011-06-22 2015-05-20 Univ Indiana Res & Tech Corp COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR
SG11201406671RA (en) 2012-04-19 2014-11-27 Opko Biolog Ltd Long-acting oxyntomodulin variants and methods of producing same
US9340600B2 (en) 2012-06-21 2016-05-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
KR101373563B1 (ko) 2012-07-25 2014-03-12 전북대학교산학협력단 Ｔｏｆ-ｍｒａ를 이용한 혈류특성 및 ｍｒ-신호강도구배(전단율) 유도방법
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
KR102311517B1 (ko) * 2012-11-06 2021-10-14 한미약품 주식회사 옥신토모듈린과 면역글로불린 단편을 포함하는 단백질 결합체의 액상 제제
JP6137046B2 (ja) 2014-05-09 2017-05-31 信越化学工業株式会社 単量体、高分子化合物、レジスト材料及びパターン形成方法
TWI772252B (zh) * 2014-09-16 2022-08-01 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102056606A (zh) * 2008-06-03 2011-05-11 贝林格尔.英格海姆国际有限公司 用于治疗非酒精性脂肪肝疾病的dpp-iv抑制剂
CN102123723A (zh) * 2008-06-17 2011-07-13 印第安纳大学研究及科技有限公司 胰高血糖素/glp-1受体共激动剂
CN102459325A (zh) * 2009-06-16 2012-05-16 印第安纳大学科技研究有限公司 胃抑胜肽受体活化的胰高血糖素化合物
CN102781458A (zh) * 2009-11-23 2012-11-14 安米林药品公司 多肽缀合物
CN103338760A (zh) * 2010-11-15 2013-10-02 贝林格尔.英格海姆国际有限公司 保护血管及保护心脏的抗糖尿病性治疗
CN103402536A (zh) * 2010-12-22 2013-11-20 马克迪亚生物科技公司 用gip和glp-1受体活性的基于胰高血糖素的肽来治疗代谢异常和肥胖的方法
CN103596595A (zh) * 2011-06-02 2014-02-19 韩美科学株式会社 用于治疗糖尿病的包括长效胰岛素缀合物和长效促胰岛素肽缀合物的组合物
CN103906528A (zh) * 2011-06-24 2014-07-02 安米林药品有限责任公司 用glp-1受体激动剂的缓释制剂治疗糖尿病的方法
TW201340981A (zh) * 2012-03-09 2013-10-16 Hanmi Science Co Ltd 用於預防或治療非酒精性脂肪肝疾病之醫藥組合物
WO2014017843A1 (en) * 2012-07-25 2014-01-30 Hanmi Pharm. Co., Ltd. Composition for treating hyperlipidemia comprising oxyntomodulin derivative
KR20140018462A (ko) * 2012-07-25 2014-02-13 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Exendin-4 Improves Nonalcoholic Fatty Liver Disease by Regulating Glucose Transporter 4 Expression in ob/ob Mice.;Seok Kim1 et al.;《Korean J Physiol Pharmacol》;20140831;第18卷(第4期);第333-339页 *
Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice.;Alessandro Pocai et al;《Diabetes》;20090714;第58卷(第10期);第2260页右栏第1段-2261页右栏第1段，图2-3，表1 *
Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase.;Shani Ben-Shlomo et al;《Journal of Hepatology》;20101026;第54卷(第6期);第1214-1223页 *
Review on the effect of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for the treatment of non-alcoholic fatty liver disease.;Chao-lin LI et al;《J Huazhong Univ Sci Technolog Med Sci》;20150601;第35卷(第3期);第333-336页 *
Treatment with exendin-4 improves the antidiabetic efficacy and reverses hepatic steatosis in glucokinase activator treated db/db mice.;Nirav Dhanesha et al;《European Journal of Pharmacology》;20130625;第714卷(第1期);第188-192页 *

Also Published As

Publication number Publication date
JP6832273B2 (ja) 2021-02-24
CN107106660A (zh) 2017-08-29
EP3197483A1 (en) 2017-08-02
PH12017500486B1 (en) 2017-08-07
AU2021203106A1 (en) 2021-06-10
AR101896A1 (es) 2017-01-18
AU2015318881A1 (en) 2017-03-30
KR102541971B1 (ko) 2023-06-13
MX2022007012A (es) 2022-06-17
SG11201701841WA (en) 2017-04-27
ZA201701847B (en) 2020-10-28
PE20170778A1 (es) 2017-07-04
WO2016043533A1 (en) 2016-03-24
KR20230091840A (ko) 2023-06-23
IL251060B (en) 2019-09-26
IL268702A (en) 2019-09-26
IL268702B (en) 2020-11-30
IL251060A0 (en) 2017-04-30
US10233230B2 (en) 2019-03-19
AU2024227659A1 (en) 2024-11-14
CA2960657A1 (en) 2016-03-24
TW202233240A (zh) 2022-09-01
ZA201903822B (en) 2021-02-24
KR102762409B1 (ko) 2025-02-05
US20170298117A1 (en) 2017-10-19
MX2017003438A (es) 2017-11-13
KR20250024003A (ko) 2025-02-18
KR20160032699A (ko) 2016-03-24
MY195618A (en) 2023-02-02
JP2017529354A (ja) 2017-10-05
MY178378A (en) 2020-10-09
JP2021035942A (ja) 2021-03-04
MA40466A (fr) 2016-03-24
NI201700032A (es) 2017-06-22
TWI802396B (zh) 2023-05-11
EA201790568A1 (ru) 2017-07-31
CL2017000638A1 (es) 2017-11-03
AU2021203106B2 (en) 2024-11-14
GT201700056A (es) 2019-08-09
CR20170129A (es) 2017-05-22
US10435459B2 (en) 2019-10-08
TWI772252B (zh) 2022-08-01
ECSP17022931A (es) 2018-04-30
NZ730799A (en) 2021-07-30
CO2017002689A2 (es) 2017-06-30
EP3197483A4 (en) 2018-05-09
TW201625303A (zh) 2016-07-16
PH12017500486A1 (en) 2017-08-07
BR112017004934A2 (pt) 2017-12-12
US20190169271A1 (en) 2019-06-06

Similar Documents

Publication Publication Date Title
KR102762409B1 (ko) 지속형 glp-1/글루카곤 수용체 듀얼 아고니스트의 비알콜성 지방간질환에 대한 용도
JP7341263B2 (ja) オキシントモジュリン誘導体を含む糖尿病又は肥満性糖尿病の治療用組成物
JP6903086B2 (ja) オキシントモジュリン誘導体を含む高脂血症の治療のための組成物
JP2022025114A (ja) 非アルコール性脂肪肝疾患の予防または治療のための医薬組成物
HK1238162A1 (en) Use of a long acting glp-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease
HK1238162B (zh) 长效glp-1/胰高血糖素受体双激动剂对於治疗非酒精性脂肪肝疾病的应用
EA042870B1 (ru) Применение двойного агониста рецепторов glp-1/глюкагона пролонгированного действия для лечения неалкогольной жировой болезни печени
NZ752300A (en) Use of a long acting glp-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease
HK1211856B (en) A composition for treating diabetes or diabesity comprising oxyntomodulin analog

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1238162

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant